|
|
Title: Hemostatic soluble cellulose fibers containing
coagulating protein for treating wound and process for producing the same
United States Patent: 7,351,422
Issued: April 1, 2008
Inventors: Jo; Yoshio (Tokyo, JP),
Aoshima; Motonori (Tokyo, JP), Tanabe; Koji (Tokyo, JP), Matsushita; Koichi (Tokyo, JP), Inoue;
Toshiki (Tokyo, JP)
Assignee: Hogy Medical Co., Ltd. (Minato-ku,
Tokyo, JP)
Appl. No.: 10/069,561
Filed: February 22, 2001
PCT Filed: February 22, 2001
PCT No.: PCT/JP01/01285
371(c)(1),(2),(4) Date: October 22, 2001
PCT Pub. No.: WO01/62278
PCT Pub. Date: August 30, 2001
|
|
|
Web Seminars -- Pharm/Biotech/etc.
|
Abstract
Proposed is a novel soluble trauma-healing and hemostatic cellulose
fiber capable of absorbing and readily dissolving hemorrhaging trauma loci
when applied thereto and of promoting the hemostatic action of blood
platelets and fibrin and cell adhesion to the trauma site. The coagulation
protein-containing soluble trauma-healing and hemostatic cellulose fiber
is produced in that after treatment of a natural or regenerated cellulose
fiber with an aqueous sodium hydroxide solution, said fiber is
carboxymethylated by reaction with a monochloro acetic acid solution for a
given time (hours) in such a manner that the degree of partial
substitution of the glucose units constituting the cellulose molecule
(etherification degree) is 0.5-less than 1.0% and that, furthermore, the
coagulation proteins fibrinogen, thrombin, and coagulation factor XIII are
imparted by surface application or chemical bonding.
Description of the
Invention
SUMMARY OF THE INVENTION
In order to overcome the above difficulties, the inventors of the present
application have conducted intensive investigations and found that soluble
trauma-healing hemostatic cellulose fiber containing coagulation protein has
a superior absorbency in tissue fluids, including blood, is readily
dissolved on contact with blood, and even when the coagulation cascade is
not active, it will exhibit a hemostatic effect due to stimulation of the
agglutination reaction of fibrin monomer which is formed from fibrinogen by
the action of the thrombin present in the coagulation protein-containing
soluble trauma-healing hemostatic cellulose fiber and as a result of the
stabilization of the agglutinates through a cross-linking reaction of the
coagulation factor XIII that is contained in said soluble trauma-healing
hemostatic cellulose fiber. In other words, the coagulation
protein-containing soluble trauma-healing hemostatic cellulose fiber
accelerates the agglutination of fibrin monomer formed through the action of
thrombin regardless of the activation of the enzymes involved in the
coagulation cascade reaction and, furthermore, promotes the adhesion and
agglutination of the platelets to the trauma locus due to the rapid
dissolving thereof on contact with the blood or body fluids present in the
trauma site. It has thus been found to promote the adhesion activity of the
fibronectin cells.
Thus, the invention according to this application refers to a material
obtained by the application of coagulation proteins to a natural or
regenerated cellulose fiber whose hydroxyl groups in the glucose units
constituting the cellulose molecule have been partially carboxymethylated in
such a manner that the carboxymethyl substitution level (etherification
degree) becomes 0.5-under 1.0%, and relates to a material consisting of a
coagulation protein-containing soluble trauma-healing hemostatic cellulose
fiber obtained by a process in which, after treatment of the natural or
regenerated cellulose fiber in sodium hydroxide, the hydroxyl groups of the
glucose units constituting the cellulose molecule are partially
carboxymethylated by allowing said fiber to react with a monochloroacetic
acid for a certain reaction time, preferably 4-18 hours, in such as manner
that the substitution level (etherification degree) becomes 0.5-under 1,0%
with subsequent purification and in which, furthermore, the refined product
is imparted with fibrinogen, thrombin and coagulation factor XIII as the
coagulation proteins with subsequent drying.
The coagulation proteins are imparted by way of application to the aforesaid
carboxymethylated natural or regenerated cellulose fiber or by way of
chemical boding to the aforesaid carboxymethylated natural or regenerated
cellulose fiber (that is to say, a means other than the physical bonding
brought about by surface application).
Moreover, surface application of the coagulation proteins may be
accomplished in practice, by way of example, by spraying a solution
containing said coagulation proteins on to the aforesaid carboxymethylated
natural or regenerated cellulose fiber. In this event, the coagulation
proteins may be applied singly in a combination consisting of all of the
three proteins referred to herein above, namely, fibrinogen, thrombin and
coagulation factor XIII, or individually in successive order by first
applying fibrinogen, then thrombin and finally the coagulation factor XIII.
In contrast, chemical bonding of the coagulation proteins maybe
accomplished, byway of example, by chemical reaction involving the addition
of a solution containing said coagulation proteins to the aforesaid
carboxymethylated natural or regenerated cellulose fiber which has been
treated with a carbodiimide reagent. In this event, the coagulation proteins
may be added for chemical reaction singly in a combination consisting of all
of the three proteins referred to herein above, namely, fibrinogen, thrombin
and coagulation factor XIII, or individually in successive order by first
adding for chemical bonding fibrinogen, then thrombin and finally the
coagulation factor XIII.
Furthermore the invention according to the present application refers to a
product obtained by pulverizing the aforesaid carboxymethylated natural or
regenerated cellulose fiber imparted with the coagulation proteins as
described herein above after imparting said coagulation proteins thereto and
after drying. Said powder may be obtained by pulverizing the aforesaid
natural or regenerated cellulose fiber imparted with the three coagulation
proteins, namely, fibrinogen, thrombin and coagulation factor XIII, in
combination by single application or chemical bonding or, alternatively, by
pulverizing the aforesaid natural or regenerated cellulose fiber imparted
with the three coagulation proteins, namely, fibrinogen, thrombin and
coagulation factor XIII, in successive order by consecutive application or
chemical bonding with the subsequent mixing thereof.
Moreover, in accordance with the invention of this application, the
aforesaid natural or regenerated cellulose fiber imparted with the three
coagulation proteins is a drawn thread array consisting of a number of
single threads loosely twisted together or a woven fabric produced either by
plain-weaving or twill-weaving a drawn thread array consisting of a number
of single threads loosely twisted together, whereby the thickness of the
drawn thread array corresponds to a Denier number comprised between 20-100.
Furthermore, the invention according to the present application relates to a
gauze-like product obtained by converting the aforesaid natural or
regenerated cellulose fiber to a wool either before or after imparting the
coagulation proteins thereto.
Furthermore, the invention according to the present application relates to
product obtained by pulverizing, after imparting said coagulation proteins,
the aforesaid natural or regenerated fibers in the form of a drawn thread
area or a woven fabric or a gauze.
Moreover, the invention according to this application relates to a product
consisting of coagulation protein-containing soluble trauma-healing
blood-stilling cellulose fiber prepared in the manner afore-described with
an enhanced hemostatic healing effect when applied to the trauma site.
Moreover, the preferred coagulation protein-containing soluble
trauma-healing blood-stilling cellulose fiber in accordance with the
invention of the present application-may be represented by the following
summary Chemical formula 1 or Chemical formula 2 (see Original Patent) as the structural units
constituting the cellulose. Chemical formula 1 represents the arrangement in
which the coagulation proteins have been imparted by surface application and
Chemical formula 2 (see Original Patent) an arrangement in which the coagulation proteins have
been imparted by chemical bonding.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following descriptions use embodiments of the practical preparation of
the soluble trauma-healing hemostatic cellulose containing coagulation
protein and examples of tests for achieving the trauma-healing and
hemostatic effects.
As an example for the execution of the preparation of the soluble
trauma-healing hemostatic cellulose, the Japanese Patent Application No.
Hei11-58412 describes a method for the preparation of soluble trauma-healing
hemostatic cellulose whereby 70 g of natural or regenerated cellulose fiber
formed into a fabric obtained by drawing an array of 20 loosely twisted
fibers and by one-two twill-weaving the drawn fiber array with a thickness
of 40 Denier, was introduced into a 1000 mL rotary reaction vessel to which
were added 250 mL of sodium hydroxide--ethanol solution consisting of 38
volume parts of a 45% aqueous sodium hydroxide solution and 62 volume parts
of 95% ethanol, with subsequent thorough impregnation and stirring for 2
hours at 25 degrees C. Following this, addition was made to this reaction
solution of 210 mL of a monochloro acetic acid reaction solution consisting
of 40 volume parts of monochloro acetic acid and 60 volume parts of 95%
ethanol, with subsequent stirring for 4-18 hours. After the reaction had
reached completion, the hydrogen ion index (pH value) of the solution
containing the fibers thus obtained was adjusted to 7.0 with 20%
hydrochloric acid, whereupon the fibers were washed with a 60-95% aqueous
ethanol solution until the sodium chloride content of the fibers we 1% or
less. The cellulose fiber treated in this manner was then dried and
sterilized to obtain a soluble trauma-healing hemostatic cellulose with the
target etherification degree (level of carboxymethyl group substitution) of
0.5-1.0%. The "soluble trauma-healing hemostatic cellulose fibers" mentioned
in the test examples below shall be interpreted as the soluble
trauma-healing hemostatic cellulose fibers obtained by the afore-described
means, unless where specifically stated otherwise.
Next, in test example 1 (see Original Patent), the etherification degree corresponding to the
stirring time with the monochloro acetic acid reaction solution was
determined in order to ascertain that the degree of etherification (carboxymethyl
group substitution) of the soluble trauma-healing hemostatic cellulose
fibers thus obtained was within the range of 0.5-1.0%. The measurement
method was such that 1 g of each of the soluble trauma-healing hemostatic
cellulose fibers produced by stirring with the monochloro acetic acid
solution 2, 4, 8, 14, and 18 hours, respectively, in the aforesaid test
example was cut into fine pieces, transferred into a tapering triangular (50
mL) flask, added with 25 mL of anitricaid-methanol solution (using a
solution prepared by mixing 100 mL of methanol and 10 mL of nitric acid),
shaken for 1 hour and used as the hydrogen type sample. Following this, the
sample was trapped by absorptive filtration in a glass filter (G3), washed
with 120 mL (three times using 40 mL each time) with an 800 g/L aqueous
methanol solution (mixture of 100 mL of anhydrous methanol and 20 mL of
water), and finally washed with 25 mL of anhydrous methanol, whereupon the
sample was passed through an absorption filter and the sample on the filter
was dried at 105 degrees C. for 2 hours. Furthermore, 0.2 g of the hydrogen
type sample was accurately weighed, placed in a (100 mL) tapering triangular
flask, added with 8 mL of 800 g/L methanol and 20 mL of a standard 0.1 mol/L
sodium hydroxide solution and shaken for 30 minutes at 25 degrees C. to
convert the hydrogen type sample to the sodium type. Moreover, the excess
sodium hydroxide was then determined by titration with a sulfuric acid of a
known titer of 0.05 mol/L using phenolphthalein as the indicator in order to
determine the etherification degree therefrom. Table 1 (see Original Patent) presented the
measurement results.
As can be seen from the results presented in Table 1 (see Original Patent), when the
reaction time with monochloro acetic acid is four hours or more it is
possible to produce a soluble trauma-healing hemostatic cellulose having a
degree of substitution of 0.5% or more. Consequently, it is possible to
control the degree of carboxymethyl group substitution by controlling the
reaction time with monochloro acetic acid.
Next, in test example 2 (see Original Patent), the method of preparation of soluble trauma-healing hemostatic cellulose fibers containing coagulation protein is explained,
being a method for the application of coagulation protein to soluble
trauma-healing hemostatic cellulose fibers and natural or regenerated
cellulose fibers. There are two different methods of imparting coagulation
protein, one of which is the application and the other one the chemical
bonding method, and each will be explained herein below.
First, while the soluble trauma-healing hemostatic cellulose fibers are
soluble in water, in the case of an aqueous solution containing 60% of
ethanol or more the fiber will not dissolve and can thus be preserved as
fiber so that the application method may consist of a procedure by which a
soluble trauma-healing hemostatic cellulose fiber containing coagulation
protein is obtained by application in such a manner that 0.2 mL of a 60%
ethanol solution containing, as coagulation proteins, 5 mg of fibrinogen,
1.5 units of thrombine, and 8 units of blood coagulation factor XIII, is
uniformly sprayed on to 15.6 mg (1 cm.sup.2) of soluble trauma-healing
hemostatic cellulose fiber prepared in accorance with the embodiment
described above (with a reaction time of 14 hours with monochloro acetic
acid) while allowing to dry with a fan.
Conversely, the chemical bonding method takes place by a procedure involving
the use of carbodiimide in such a manner that 15.6 mg of the soluble
trauma-healing hemostatic cellulose fiber (fiber obtained by reaction with
monochloroacetic acid for 14 hours) produced in accordance with the
afore-described embodiment is introduced into a 5 mL capacity glass test
tube and after addition of 1 mL of a 60% ethanol solution, 38 mg of
1-ethyl-3-(3-dimethyl amino propyl) carbodiimide is added with subsequently
stirring at 30 degrees C. for 2 hours, whereupon the reaction solution is
removed and the soluble trauma-healing hemostatic cellulose fiber treated
with said carbodiimide is washed three times with 3 mL of a 60% ethanol
solution. Next, addition is made thereto of 1 mL of a 60% ethanol solution
containing, as coagulation proteins, 5 mg of fibrinogen, 1.5 units of
thrombine, and 8 units of blood coagulation factor XIII for reaction at 30
degrees C. for 2 hours. In order to block the unreacted carboxyl groups,
addition is made of 29 mg of L-lysine and after allowing to react at 30
degrees C. for 1 hours, the reaction solution is removed and the
post-reaction soluble trauma-healing hemostatic cellulose fiber is washed
three times with 3 mL of a 60% ethanol solution and once with 3 mL of a 95%
ethanol solution. Following this, said soluble trauma-healing hemostatic
cellulose fiber is dried at 50 degrees C. for five minutes to obtained a
soluble trauma-healing hemostatic cellulose fiber with chemically bonded
coagulation protein.
Following this, the solubility of the coagulation protein-containing soluble
trauma-healing hemostatic cellulose fiber in a 0.95% sodium chloride (salt)
solution and in pure water is measured as a third test example in order to
ascertain the solubility of the coagulation protein-containing soluble
trauma-healing hemostatic cellulose fiber obtained by either of the
aforesaid method, namely, surface application and chemical bonding. The
method by which these measurements are carried out is to add 0.1 g of the
coagulation protein-containing soluble trauma-healing hemostatic cellulose
fiber obtained by either of said methods 100 mL of an 0.95% aqueous salt
solution and an equal volume of pure water, respectively, (so that the
concentration of said fiber becomes 0.1 w/v %) and measure by visual
inspection the time required until the insoluble parts have completely
disappear while continuing to stir at 25 degrees C. The results are reported
in Table 2 (see Original Patent).
As can be seen from the results presented in Table 2 herein above,
coagulation protein-containing soluble trauma-healing hemostatic cellulose
fiber in accordance with the invention of this Application is readily and
completely soluble, without fail, in pure water and in saline water
regardless of whether said coagulation protein is imparted by way of surface
application or by chemical bonding methods.
Given as a fourth test example is the measurement of the 350 nm absorption
degree using an ultraviolet spectrophotometer U-3210 (manufactured by
Hitachi, Ltd.) in order to ascertain the fibrimonomer coagulation activity
of the coagulation protein-containing soluble trauma-healing hemostatic
cellulose fiber obtained by either of the for said method, namely, surface
application and chemical bonding. For the measurement conducted in the
presence of the 1 w/v % coagulation protein-containing soluble
trauma-healing hemostatic cellulose fiber obtained by either of the
aforesaid method (namely, surface application and chemical bonding), 20 .mu.L
of fibrimonomer (A280 nm=6)dissolved in 20 mmol/L of acetic acid was added
to 500 .mu.L of 20 mmol/L imidazol buffer solution (pH7.4) containing 0.15
mol/L of sodium chloride (NaCl) in the presence of the soluble
trauma-healing hemostatic cellulose fiber (that is, soluble trauma-healing
hemostatic fiber obtained without imparting coagulation protein and in the
absence of soluble trauma-healing hemostatic cellulose fiber (control), and
20 seconds after of fibrinomer 350 nm absorptivity was measured every 30
seconds for 25 minutes. The results of these measurements are reported in
FIG. 1 (see Original Patent).
As can be seen from the results assembled in FIG. 1, the coagulation
protein-containing soluble trauma-healing hemostatic cellulose fiber is
capable of substantially promoting the coagulation of fibrinomer, regardless
of whether said coagulation protein is imparted by way of surface
application or by chemical bonding methods, and it can be recognized
furthermore, that the fibrinomer coagulation activity is much superior as
compared with a soluble trauma-healing hemostatic cellulose fiber to which
no coagulation protein has been imparted.
Next, in test example 5 (see Original Patent), the platelet agglutination ability has been
measured using a platelet agglutination test unit (manufactured by Mebanics)
in order to ascertain the platelet agglutination promoting activity of the
coagulation protein-containing soluble trauma-healing hemostatic cellulose
fiber obtained by either of the aforesaid methods, namely, surface
application and chemical bonding, and to establish the significantly
superior platelet agglutination promoting activity of the aforesaid
coagulation protein-containing soluble trauma-healing hemostatic cellulose
fiber as compared with the soluble trauma-healing hemostatic cellulose fiber
to which no coagulation protein has been imparted. For the measurement of
the platelet agglutination ability, 20 mmol/L imidazol buffer solution
containing 0.15 mol/L of sodium chloride (NaCl) in the presence of the
soluble trauma-healing hemostatic cellulose fiber (that is, soluble
trauma-healing hemostatic cellulose fiber obtained without imparting
coagulation protein and in the absence of soluble trauma-healing hemostatic
cellulose fiber, was mixed with platelet-rich plasma at a ratio of 1:1 and
adenosine diphosphate (ADP) was added at concentrations corresponding to its
function as a platelet agglutination agent to determine the platelet
agglutination ability by measuring the turbidity of the reaction solution.
The results of the measurements are presented in Table 3 (see Original Patent).
As can be seen from the results presented in Table 3 and FIG. 2 (see Original Patent), the
coagulation protein-containing soluble trauma-healing hemostatic cellulose
fiber is capable of substantially promoting platelet agglutination,
regardless of whether said coagulation protein is imparted by way of surface
application or by chemical bonding methods, and it can be recognized
furthermore, that the platelet agglutination activity is much superior as
compared with a soluble trauma-healing hemostatic cellulose fiber to which
no coagulation protein has been imparted.
Next, in test example 6 (see Original Patent), the cell adhesion ability has been measured by
determining the adhered cell count in a given field of view in order to
ascertain the cell adhesion promoting activity of the coagulation
protein-containing soluble trauma-healing hemostatic cellulose fiber
obtained by either of the aforesaid methods, namely, surface application and
chemical bonding, and to establish the cell adhesion promoting activity of
the aforesaid coagulation protein-containing soluble trauma-healing
hemostatic cellulose fiber and to demonstrate the superior cell adhesion
ability thereof as compared with the soluble trauma-healing hemostatic
cellulose fiber to which no coagulation protein has been imparted. For this
purpose, the adhered cell count upon addition of the respective soluble
trauma-healing hemostatic cellulose fiber containing 1 w/v % coagulation
protein imparted by either of said methods, and the adhered cell count upon
addition of soluble trauma-healing hemostatic cellulose fiber (that is,
soluble trauma-healing hemostatic cellulose fiber not containing coagulation
protein), and the adhered cell count without addition of soluble
trauma-healing hemostatic cellulose fiber were determined. The measurement
of the adhered cell count was made in such a manner that 96 well plates were
covered with the cell adhesion proteins fibrinectin, vitronectin, laminin,
collagen and fibrin, respectively, at the various concentrations, and that
5,000 NIH-3T3 were then introduced thereon to determine the respective
adhesion protein concentrations at which no cell adhesion activity is in
evidence by determining the given adhered cell count in a given field of
view after six hours and by determining the adhered cell count in a given
field of view following the addition of 1 w/v % coagulation
protein-containing soluble trauma-healing hemostatic cellulose fiber
obtained by either of the aforesaid method or soluble trauma-healing
hemostatic cellulose fiber, respectively, and, alternatively, without any
addition whatsoever. The results of these measurements are reported in Table
4 (see Original Patent).
As can be seen from the results presented in Table 4, the coagulation
protein-containing soluble trauma-healing hemostatic cellulose fiber
exhibits a substantially higher adhered cell count, regardless of whether
said coagulation protein is imparted by way of surface application or by
chemical bonding methods, and it can thus be recognized that said
coagulation protein-containing soluble trauma-healing hemostatic cellulose
fiber possess a cell adhesion promoting activity, and that, furthermore, the
cell adhesion promoting activity of said coagulation protein-containing
soluble trauma-healing hemostatic cellulose fiber is significantly superior
to that of the soluble trauma-healing hemostatic cellulose fiber to which no
coagulation protein has been imparted.
Next, in test example 7 (see Original Patent), measurements have been conducted in order to
determine the blood-stilling or hemostatic effect and the trauma-healing
effect by using coagulation protein-containing soluble trauma-healing
hemostatic cellulose fiber obtained by either of the aforesaid methods,
namely, surface application and chemical bonding, on the trauma site, and in
order to establish the substantially superior blood-stilling or hemostatic
effect and the trauma-healing effect thereof as compared with the soluble
trauma-healing hemostatic cellulose fiber to which no coagulation protein
has been imparted. For this purpose, the time required for hemostasis to
occur upon administration to the trauma site of the respective soluble
trauma-healing hemostatic cellulose fiber containing 1 w/v % coagulation
protein imparted by either of said methods and the extent of healing of the
trauma, the time required for hemostasis to occur upon administration to the
trauma site of the soluble trauma-healing hemostatic cellulose fiber not
containing coagulation protein and the extent of healing of the trauma site,
and the time required for hemostasis to occur without administration to the
trauma site of the respective soluble trauma-healing hemostatic cellulose
fiber and the extent of healing of the trauma site were determined. The
hemostasis time was determined by resecting 1 cm.times.1 cm square patches
of liver from 10 rats and attaching to the trauma site coagulation
protein-containing soluble trauma-healing hemostatic cellulose fiber and
soluble trauma-healing hemostatic cellulose fiber, respectively, and
attaching no soluble trauma-healing hemostatic cellulose fiber (whatsoever),
respectively, to measure the time required for hemostasis to occur
(seconds), whereby a comparison was made with the hemostasis effect
associated with the untreated trauma and that associated with the fiber to
which no coagulation protein had been imparted; and, furthermore, the extent
of healing was determined by attaching to the trauma site the respective
soluble trauma-healing hemostatic cellulose fiber containing coagulation
protein imparted by either of said methods, closing the abdominal section
after the hemostatis time had been measured, performing laparotomy one month
later and taking a pathology section of the trauma site for preparation and
microscopic observation for visual assessment of the degree of healing. The
results of the measurements are reported in Table 5 (see Original Patent). For the determination
of the extent of healing of the trauma site, the specimens equivalent to the
normal condition were marked with the .circleincircle. sign, those
exhibiting some slight inflammation with the .largecircle. sign and those
showing complete healing of the inflammatory processes with the X sign.
As can be seen from the results presented in Table 5, soluble trauma-healing
hemostatic cellulose fiber has a substantial blood-stilling or hemostatic
effect, and the ten rats treated with soluble trauma-healing hemostatic
cellulose fiber exhibited a virtually complete healing without any signs of
inflammation whatsoever, and it can therefore be recognized that coagulation
protein-containing soluble trauma-healing hemostatic cellulose fiber possess
a substantial hemostatic and trauma-healing effect as compared with soluble
trauma-healing hemostatic cellulose, regardless of whether said coagulation
protein is imparted by way of surface application or by chemical bonding
methods.
The coagulation protein-containing soluble trauma-healing hemostatic
cellulose fiber produced as described herein above and in accordance with
the invention of this Application absorbs both blood and tissue fluid when
applied to the trauma site, regardless of whether said coagulation protein
is imparted by way of surface application or by chemical bonding methods,
increases the concentration and viscosity of the blood and the tissue fluid,
and generates potent fibrin agglutinates under the action of the fibrinogen,
thrombin and coagulation factor XIII contained in said coagulation
protein-containing soluble trauma-healing hemostatic cellulose fiber,
thereby exhibiting a powerful blood-stilling or hemostatic effect in such as
manner as to reduce the flow (rate) of the blood and tissue fluid; and
exihiting, furthermore, a blood-stilling or hemostatic effect by assisting
platelet adhesion to, and platelet agglutination in, the trauma site.
Moreover, coagulation protein-containing soluble trauma-healing hemostatic
cellulose fiber in accordance with the inventions of the present Application
interacts with the adhesion proteins such as fibronectin and promotes the
growth of fibroblasts which play an important role in the trauma healing
process.
While the explanations concerning the test examples described herein above
refer to the sodium salt of the coagulation protein-containing soluble
trauma-healing hemostatic cellulose fiber, the invention according to the
present Application is not limited thereto but may, without any limitation
whatsoever, also refer to the calcium salt of the coagulation
protein-containing soluble trauma-healing hemostatic cellulose fiber or to
mixtures of a multiplicity of salts thereof.
Whereas, furthermore, all of the explanations concerning the test examples
described herein above refer to a coagulation protein-containing soluble
trauma-healing hemostatic cellulose fiber formed into a fabric the invention
according to the present Application is not limited thereto but may
naturally also apply to a product formed into a powder by subjecting the
threadlike or fabric-like coagulation protein-containing soluble
trauma-healing hemostatic cellulose fiber to a pulverization treatment or to
a product formed into a gauze material by subjecting the threadlike or
fabric-like coagulation protein-containing soluble trauma-healing hemostatic
cellulose fiber to a shoddy wool treatment, provided that any such
coagulation protein-containing soluble trauma-healing hemostatic cellulose
fiber product does exhibit a trauma-healing and hemostatic effect as being
the purpose of the present invention.
As explained herein above, the coagulation protein-containing soluble
trauma-healing hemostatic cellulose fiber in accordance with the invention
of the present Application has an extremely speedy blood-stilling or
hemostatic effect, presents a speedy in-vivo absorption behavior virtually
without giving rise to any inflammatory reactions and exhibits a high
trauma-healing effect.
Furthermore, the coagulation protein containing soluble trauma-healing and
hemostatic material in accordance with the invention of the present
Application is capable of producing a trauma-healing effect based on its
ability to promote hemostasis and cell adhesion in the trauma site at high
efficiency; wherefore it is eminently effective a a hemostatic and
trauma-healing material for both internal and external application and has a
significant scope for potential application in a wide range of uses as a
trauma-covering hemostatic material capable of enhancing the healing effect
of the trauma locus.
Claim 1 of 38 Claims
1. A soluble trauma-healing hemostatic
cellulose fiber, comprising a natural or regenerated cellulose fiber that
has been partially carboxymethylated to an extent such that degree of
substitution of the hydroxyl groups in the glucose units constituting the
cellulose molecule is 0.5-less than 1.0, wherein three types of
coagulation proteins being fibrinogen, thrombin and coagulation factor
XIII are applied or chemically bonded to said fiber followed by drying,
such that said fiber possesses activity for accelerating a coagulation
reaction of fibrin monomers converted from fibrinogen with thrombin and
possesses activity for stabilizing agglutinates by cross-linking reaction
with the coagulation factor XIII.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|